SCHEMBL4883153

SCHEMBL4883153

OC(CN1CCN(Cc2ccc(Cl)cc2)CC1)C(O)(c1ccccc1)C1CCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.49
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
KCNH2 Q12809 3/20 0.46
HRH1 P35367 2/20 0.46
CHRM3 P20309 4/20 0.45
CHRM2 P08172 3/20 0.45
CHRM1 P11229 3/20 0.45
ALDH1A1 P00352 1/20 0.44
CACNA1G O43497 2/20 0.44
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.42
NR1I2 O75469 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
CNR1 P21554 1/20 0.42
OPRK1 P41145 1/20 0.42
PDE4D Q08499 1/20 0.42
GHSR Q92847 1/20 0.42
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4886880 0.93 CHRM3 (0.51) SIGMAR1MEN1KMT2AKCNH2HRH1
SCHEMBL4889873 0.84 MEN1 (0.56) SIGMAR1MEN1KMT2AKCNH2HRH1
SCHEMBL4881797 0.83 MEN1 (0.58) SIGMAR1MEN1KMT2AKCNH2HRH1
SCHEMBL4890266 0.83 MEN1 (0.58) SIGMAR1MEN1KMT2AKCNH2HRH1
SCHEMBL4889264 0.82 TSHR (0.53) SIGMAR1MEN1KMT2AKCNH2HRH1
SCHEMBL4885076 0.82 MEN1 (0.54) SIGMAR1MEN1KMT2AKCNH2HRH1
SCHEMBL4889974 0.81 MEN1 (0.53) SIGMAR1MEN1KMT2AKCNH2HRH1
SCHEMBL4882542 0.80 MEN1 (0.71) SIGMAR1MEN1KMT2AKCNH2HRH1
SCHEMBL4889815 0.80 MEN1 (0.52) SIGMAR1MEN1KMT2AKCNH2HRH1
SCHEMBL4887153 0.79 CHRM3 (0.50) SIGMAR1MEN1KMT2AKCNH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280883-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-11-13 US claimed
EP-1794161-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2007-06-13 EP claimed
WO-2006032994-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-03-30 WO claimed
US-20080280883-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-11-13 US disclosed
EP-1794161-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2007-06-13 EP disclosed
WO-2006032994-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280883-A1 Muscarinic Receptor Antagonists CHRM3, CHRM5, CHRM2 SIGMAR1 349/4885MEN1 1629/4885KMT2A 2763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.